Volume | 23,049 |
|
|||||
News | - | ||||||
Day High | 2.3292 | Low High |
|||||
Day Low | 2.09 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Genprex Inc | GNPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.17 | 2.09 | 2.3292 | 2.21 | 2.12 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
202 | 23,049 | $ 2.23 | $ 51,390 | - | 2.09 - 42.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:50:54 | 1 | $ 2.20 | USD |
Genprex Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.28M | 1.49M | - | 0 | -30.86M | -20.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Genprex News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.23 | 2.50 | 2.09 | 2.20 | 23,232 | -0.02 | -0.90% |
1 Month | 3.00 | 3.27 | 2.09 | 2.76 | 37,095 | -0.79 | -26.33% |
3 Months | 5.64 | 7.99 | 2.09 | 4.84 | 90,041 | -3.43 | -60.82% |
6 Months | 9.076 | 14.796 | 2.09 | 8.83 | 325,775 | -6.87 | -75.65% |
1 Year | 32.756 | 42.40 | 2.09 | 20.95 | 412,386 | -30.55 | -93.25% |
3 Years | 155.20 | 166.40 | 2.09 | 98.03 | 861,471 | -152.99 | -98.58% |
5 Years | 70.40 | 308.80 | 2.09 | 117.67 | 1,275,404 | -68.19 | -96.86% |
Genprex Description
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. |